치매 치료제 시장 : 약제 클래스별, 적응증별, 투여 경로별, 유통 채널별, 지역별

The dementia drugs market size is estimated to be valued at US$ 26.14 Bn in 2025 and is expected to reach US$ 41.45 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.8% from 2025 to 2032.

Figure. Dementia Drugs Market Share (%), By Region 2025

Dementia drugs market growth is driven by rising cases of Alzheimer's and other forms of dementia worldwide. Dementia is a syndrome caused due to disorders that affect the brain, such as Alzheimer's disease or strokes. It is characterized by a gradual loss of cognitive functions like thinking, remembering and reasoning. Increasing awareness about diagnosis and availability of treatment options drive more people to seek medical help for dementia symptoms. Several pharmaceutical companies are investing heavily in research and development of effective drugs to slow down or stop the progression of dementia.

Market Dynamics

Dementia drugs market growth is primarily driven by rapidly aging global population, which increases the risk of neurodegenerative conditions. Rising healthcare expenditures in developing nations and intensive R&D efforts by biopharmaceutical firms further contribute to market expansion. However, high drug development costs, particularly due to the failure of many candidate molecules in late-stage trials and the complexity of these diseases, pose significant challenges. The recent approval of disease-modifying drugs that aim to impact disease etiology rather than merely alleviating symptoms presents substantial opportunities for manufacturers. Increased government support and funding for dementia research are encouraging market participants to innovate and develop new therapies. As the prevalence of dementia continues to rise, driven by demographic changes, the demand for effective treatments is expected to grow, positioning the market for significant advancements.

Key features of the study

This report provides in-depth analysis of the global dementia drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global dementia drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Biogen, Eisai Co., Ltd., Novartis AG, Cipla, H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Mapi-Pharma Ltd., AbbVie, Inc., DAIICHI SANKYO COMPANY, LIMITED., and F. Hoffmann-La Roche Ltd

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global dementia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dementia drugs market

Market Segmentation

• By Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
  • MAO Inhibitors
  • Cholinesterase Inhibitors
  • Glutamate Inhibitor
  • Others
• By Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Alzheimer's Disease Dementia
  • Lewy Body Dementia
  • Parkinson Disease Dementia
  • Others
• By Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Intravenous
  • Others
• By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles:
  • Biogen
  • Eisai Co., Ltd.
  • Novartis AG
  • Cipla
  • Lundbeck A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Mapi-Pharma Ltd.
  • AbbVie, Inc.
  • DAIICHI SANKYO COMPANY, LIMITED.
  • Hoffmann-La Roche Ltd

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Dementia Drugs Market, By Drug Class
  • Dementia Drugs Market, By Indication
  • Dementia Drugs Market, By Route of Administration
  • Dementia Drugs Market, By Distribution Channel
  • Dementia Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology
• Pipeline Analysis

4. Dementia Drugs Market, By Drug Class, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• MAO Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cholinesterase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Glutamate Inhibitor
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Dementia Drugs Market, By Indication, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Alzheimer's Disease Dementia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Lewy Body Dementia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parkinson Disease Dementia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Dementia Drugs Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Dementia Drugs Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Dementia Drugs Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Biogen
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eisai Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cipla
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Lundbeck A/S
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Otsuka Pharmaceutical Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Viatris Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mapi-Pharma Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• DAIICHI SANKYO COMPANY, LIMITED.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hoffmann-La Roche Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us